after joining the study, a series of initial examinations are performed to record the current condition of the disease. these may include medical history, physical examination, laboratory tests, and imaging of the intestines. the information collected serves as a reference point for later comparisons.

the participant is assigned, by a computer system, to one of two groups without knowing which group is received. this process ensures that the assignment is unbiased. the two possible groups are the test medication JNJ-78934804 (which contains guselkumab and golimumab) or the comparator medication guselkumab alone.

the first dose of the assigned medication is given by subcutaneous injection (injection under the skin). the exact amount of the drug and the schedule for additional doses are defined by the study protocol and will continue for the duration of the trial, which lasts up to week 48. the test medication is supplied as a solution for injection, while the comparator is provided in a pre‑filled syringe.

throughout the study, the participant attends scheduled visits to check for any side effects, to have blood drawn for laboratory tests, and to answer questionnaires about symptoms. these visits also provide any additional doses of the medication according to the predetermined schedule.

at the end of week 48, doctors assess two main outcomes: clinical remission (meaning the signs and symptoms of Crohn’s disease have improved to a predefined level) and endoscopic remission (meaning the lining of the intestine looks healed when examined with an endoscope). the results determine whether the test medication performed better than the comparator.

after the week 48 assessment, the participant’s involvement in the trial ends. any further medical care will be managed by the participant’s regular healthcare provider.